Literature DB >> 33523266

Endoscopic recanalization of complete esophageal obstruction.

Francesco Vitali1, Andreas Nägel1, Lukas Pfeifer1, Martin Goetz2, Jürgen Siebler1, Markus F Neurath1, Timo Rath3.   

Abstract

BACKGROUND AND AIMS: Complete esophageal obstruction (CEO) is a rare complication after radiochemotherapy that dramatically impairs quality of life. Within this study, we assessed the outcome of two different endoscopic techniques for lumen restoration in patients with CEO.
METHODS: 17 patients were included. Esophageal recanalization was performed in an antegrade approach (Group A) or through combined antegrade and retrograde recanalization and dilatation (CARD, Group B). Technical success, complications, and dysphagia development during follow-up (FU) were compared between the groups.
RESULTS: In Group A (n = 6), esophageal recanalization was performed by a single endoscopist with a median duration of 47 min. In two patients, antegrade recanalization led to formation of a false lumen (i.e., submucosal tunneling) followed by mediastinitis. In Group B, 21 CARD procedures were performed in 11 patients with a technical success rate of 100%. Procedure time was longer compared to Group A; however, no intra- or postprocedural complications were observed in Group B.
CONCLUSIONS: In our experience and cohort, CARD was a successful procedure for recanalization of CEO, which exhibits a more favorable safety profile over antegrade recanalization. Further randomized studies to evaluate the treatment of CEO with CARD are needed.

Entities:  

Keywords:  CARD; Esophageal obstruction; Esophagus stenosis; Recanalization

Year:  2021        PMID: 33523266     DOI: 10.1007/s00464-021-08313-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  1 in total

1.  Safety and efficacy of combined antegrade and retrograde endoscopic dilation for complete esophageal obstruction: a systematic review and meta-analysis.

Authors:  Mahendran Jayaraj; Babu P Mohan; Harmeet Mashiana; Rajesh Krishnamoorthi; Douglas G Adler
Journal:  Ann Gastroenterol       Date:  2019-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.